硼替佐米、地塞米松和沙利度胺(VDT)化疗方案治疗复发多发性骨髓瘤(MM)的疗效及安全性

Bortezomib,Dexamethasone and Thalidomide(VDT) Chemotherapy Regimen in Treatment of Relapsed Multiple Myeloma(MM) Efficacy and Safety

目的:评价硼替佐米、地塞米松和沙利度胺(VDT)化疗方案治疗复发多发性骨髓瘤(MM)的疗效及安全性。方法:选取2006-2011年间来我院接受治疗的复发MM患者16例,采取硼替佐米联合地塞米松和沙利度胺(VDT)的化疗方案对其进行治疗,每个疗程设定为28d,分别记录这16例患者经过1、2、3个疗程治疗后疾病的缓解状况及相应的不良反应状况。结果:经过3个疗程的治疗后,经过VDT方案化疗后,总体的有效率为87.50%,治疗过程中出现的主要不良反应为血小板减少、胃肠的不良反应及周围神经病变。结论:硼替佐米、地塞米松和沙利度胺(VDT)化疗方案治疗复发多发性骨髓瘤(MM)的有效率高,不良反应少,安全性高。

Objective：Evaluation of bortezomib,dexamethasone and thalidomide （VDT） chemotherapy regimen in treatment of relapsed multiple myeloma（MM） ：efficacy and safety.Methods：2006~2011 years our hospital treatment of relapsed MM patients with 16 cases,take bortezomib in combination with dexamethasone and thalidomide（VDT） chemotherapy regimens for their treatment,each course is set to 28d,the 16 patients were recorded after 1,2,3 courses of treatment after disease remission status and corresponding adverse condition.Results：After 3 courses of treatment,after chemotherapy of VDT regimen,the overall efficiency is 87.50%,the treatment of the main adverse reactions were thrombocytopenia,gastrointestinal adverse reactions and peripheral neuropathy.Conclusion：Bortezomib,dexamethasone and thalidomide（VDT） chemotherapy regimen in treatment of relapsed multiple myeloma（MM） of the high effective rate,fewer adverse reactions,high security.